Diversified health care giant Johnson & Johnson (NYSE:JNJ) saw continued fallout from a flurry of product recalls and concerns over its manufacturing controls as investors sent the stock towards its lows over the past year. The company also didn't bother to provide a full balance sheet or cash flow statement during its fourth quarter results, leaving investors to wonder about its finances and cash flows until it files full-year financial statements with the Securities and Exchange Commission.

IN PICTURES: 6 Simple Steps To $1 Million

Fourth Quarter Recap
The earnings press release did provide an income statement that detailed a 5.5% sales decline to $15.6 billion. Of the three operating divisions, the consumer unit was the notable laggard as sales fell 15% to account for 23% of sales. Product recalls of over-the-counter medicines hit the unit, as did a hip device recall in the DePuy medical device franchise, though total medical device sales eeked out 0.1% growth to account for just over 40% of total sales. The pharma unit saw sales decline a modest 4.7% to account for the remainder of the top line, as U.S. sales fell 5.7% and international decreased 1.6%.

Geographically, sales were strongest in Asia, rising 9.7% to account for 19.2% of sales. Sales fell 8.1% in the U.S. (46.2% of total sales), 10.5% in Europe (25.6%) and 4.5% everywhere else in the Western Hemisphere (9%). Product costs fell only 5.1% but management was able to reduce selling, general and administrative costs by 8%. However, $1.1 billion in recall and related expenses sent operating income down 14.4% to $2.2 billion. Net income fell 12% to $1.9 billion, or 70 cents per diluted share.

Year End Review and Outlook
Full-year sales fell 0.5% to $61.6 billion. The lack of a restructuring charge compared to last year helped push operating income ahead to $17 billion while net income rose 8.7% to $13.3 billion, or $4.78 per diluted share.

For the coming year, management said to expect earnings between $4.80 and $4.90 per share, though there again could be a number of "special items." At best, this would represent year-over-year growth of a couple of percent. Analysts project a similar level of full-year sales growth.

Bottom Line
At the current earnings valuation, shares of J&J are cheap at 12.4 times forward expectations. This represents one of the lowest multiples in the last 20 years, but it is warranted given the quality concerns and hits to the company's once solid image. Fortunately, none of the current issues appear to be serious and the company is still growing modestly. Overall though, a number of rivals, including Medtronic (NYSE:MDT), Teva Pharmaceutical (Nasdaq:TEVA), Roche (OTC:RHHBY), and Novartis (NYSE:NVS) trade at equally appealing valuations and have their acts together in terms of product manufacturing.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  2. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  3. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  4. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  5. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  6. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  7. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  8. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  9. Stock Analysis

    GoPro's Stock: Can it Fall Much Further? (GPRO)

    As a company that primarily sells discretionary products, GoPro and its potential falls right in line with consumer trends. Is that good or bad?
  10. Stock Analysis

    Are the Brands Millennials Love a Good Buy?

    Millennials make up a very big — and thus important —c onsumer generation. So if they love a brand, its stock is likely to outperform, right?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center